ZBIO
Live News • May 30
Zenas BioPharma Submits FDA Application for Obexelimab Targeting IgG4-Related Disease Zenas BioPharma has submitted a Biologics License Application (BLA) to the U.S. FDA for obexelimab as a treatment for Immunoglobulin G4-Related Disease (IgG4-RD).
The filing is supported by positive data from the Phase 3 INDIGO trial, where obexelimab reduced the risk of IgG4-RD flare compared with placebo.
The company states that obexelimab may play an important role as a first-line therapy option for long-term management of IgG4-RD.
This BLA submission moves obexelimab into the formal U.S. regulatory review process, which can be a key milestone for any clinical-stage company with a specialty drug candidate.
Investors may want to focus on future FDA review timelines, potential label scope if approved, and the competitive context in IgG4-RD to evaluate the potential importance of this asset within Zenas BioPharma’s portfolio. Announcement • May 28
Zenas BioPharma Submits Biologics License Application To U.S. FDA For Obexelimab In Immunoglobulin G4-Related Disease Zenas BioPharma, Inc. submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration for obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD). IgG4-RD is a debilitating chronic fibro-inflammatory disease affecting multiple organ systems, often resulting in irreversible tissue damage and organ failure. Obexelimab, an investigational therapy, is a bifunctional monoclonal antibody designed to bind both CD19 and FcgRIIb to inhibit B cell function. The BLA submission is supported by the results of the Phase 3 INDIGO registrational trial of obexelimab for the treatment of IgG4-RD. In INDIGO, obexelimab met the primary endpoint, demonstrating a highly statistically significant and clinically meaningful 56% reduction in the risk of IgG4-RD flare compared to placebo (Hazard Ratio 0.44, p=0.0005) during the 52-week randomized placebo-controlled period. Obexelimab also met and demonstrated highly statistically significant activity compared to placebo on all four key secondary endpoints and was generally well tolerated. Data from the INDIGO trial will be presented during an oral session at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress in London, UK, on June 4, 2026. Obexelimab is a bifunctional monoclonal antibody designed to bind both CD19 and FcgRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. This unique inhibitory mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of the B cell lineage in chronic autoimmune disease. Obexelimab has been evaluated in eight clinical trials in a total of 383 subjects, including INDIGO. Obexelimab was well tolerated and demonstrated clinical activity across these clinical trials. The registrational Phase 3 INDIGO trial for Immunoglobulin G4-Related Disease met its primary endpoint and all four key secondary endpoints with high statistical significance. The trial continues to evaluate patients in the 3-year open label extension period, which will further build upon the largest body of clinical data reported for IgG4-RD patients to date. Enrollment in a randomized Phase 2 trial for Systemic Lupus Erythematosus is completed and Zenas expects to report topline results, including biomarker data from this trial in the fourth quarter of 2026. Major Estimate Revision • May 20
Consensus revenue estimates increase by 71% The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$21.3m to US$36.3m. Forecast losses expected to reduce from -US$4.98 to -US$4.81 per share. Biotechs industry in the US expected to see average net income decline 9.3% next year. Consensus price target broadly unchanged at US$42.13. Share price was steady at US$19.56 over the past week. 
